William Blair analyst Matt Larew has reiterated their neutral stance on MRVI stock, giving a Hold rating on October 30.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Matt Larew has given his Hold rating due to a combination of factors influencing Maravai Lifesciences Holdings. The company’s third-quarter results were below expectations, with significant declines in revenue and adjusted EBITDA compared to estimates. Despite these challenges, management has completed a strategic review and reinstated guidance for the fourth quarter, suggesting a potential stabilization and growth in non-COVID revenues.
Management’s confidence in achieving positive adjusted EBITDA and free cash flow targets by the second half of 2026 further supports a cautious optimism. While the immediate financial performance was underwhelming, the strategic initiatives and future guidance provide a basis for a Hold rating, as the company appears to be on a path to recovery and growth in the coming years.
In another report released on October 30, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $3.00 price target.